Santarelli is a Proven Leader with a Track Record of Building Successful Biotech Companies Basel, Switzerland – 29 June 2023,  Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors. Rafaèle Tordjman, former chair of Alentis, will remain on Alentis’ board. “I’m pleased to welcome Luca as Chair of our board. His experience as a serial biotech entrepreneur and Alentis board member since 2021 are of great value to our board and company,” said Dr. Roberto…

Basel, Switzerland – 21 June 2023, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Professor David Jayne, Professor of Clinical Autoimmunity at Cambridge University and Professor Josep Tabernero, Head of Medical Oncology at Vall d’Hebron University Hospital as members of its Scientific Advisory Board. “We are delighted to welcome David and Josep to our newly formed Scientific Advisory Board,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis. “They bring tremendous experience and expertise in nephrology and oncology that will be crucial as we advance…

Ph1/2 Clinical Trial in Head and Neck Squamous Cell Carcinoma Expected to Start H2 2023 Basel, Switzerland – 14 June 2023,  Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the FDA cleared an IND application for ALE.C04 as a monotherapy and in combination with pembrolizumab, in a first-in-human clinical trial in recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) that is expected to start during the second half of 2023. “With ALE.C04 we aim to treat solid tumors in a unique way. By targeting exposed CLDN1…

Basel, Switzerland – 31 May 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 company, today announced its participation in the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 2-6 in Chicago, IL, and the BIO International Convention to be held June 5-8 in Boston, MA. Alentis management will be present at the conferences. In case you want to schedule a meeting please reach out via info@alentis.ch. About Alentis Therapeutics Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is…

The grant supports the development of ALE.C04 for Claudin-1 positive tumors Basel, Switzerland – 9 May 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 company, today announced it has been selected to receive a CHF 2.4M grant from the Swiss Accelerator project to further the development of ALE.C04 for Claudin-1 (CLDN1) positive cancers.Of the original 752 applications, the Innosuisse Innovation Council selected 53 projects to receive funding across multiple industries with significant innovation potential. The total funding granted amounts to CHF 112M.“We thank the Innosuisse Innovation Council for recognising Alentis’ work in oncology, and congratulate our fellow winners,” said Dr. Roberto…

The trial confirms ALE.F02’s good safety profile, exposure and target biological activity Basel, Switzerland – 26 April 2023,  Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced results from the multiple-ascending dose (MAD) part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1 (CLDN1).The trial enrolled 24 subjects: 18 received the active drug and six received placebo across three dose levels. Participants were dosed every two weeks.Dr. Luigi Manenti, Chief Medical Officer at Alentis said: “This study is the first to target CLDN1 in humans. ALE.F02 showed good…

CLAUDIN-1 targeting antibody ALE.C04 drives single agent activity and restores anti-PD1 efficacy in solid tumors Basel, Switzerland, April 14, 2023 – Alentis Therapeutics, the Claudin-1 company, today announced that Alberto Toso, Alentis’ SVP Head of Oncology, will present at the American Association for Cancer Research Conference in Orlando, Florida on April 18th.The poster session entitled, CLAUDIN-1 targeting antibody ALE.C04 drives single agent activity and restores anti-PD1 efficacy in solid tumors, presents evidence that ALE.C04 is a highly specific humanized monoclonal antibody that recognizes a unique CLDN1-exposed epitope in different solid tumors.Non-Junctional Claudin-1 (NJ-CLDN1) is frequently overexpressed in solid tumors.…

Basel, Switzerland – 13 April 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 (CLDN1) company, is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Today, Alentis announced $105 million in Series C financing. The funding round was led by Jeito Capital together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.

Alentis ‘Shares Their Colors’ for ANCA-Associated Glomerulonephritis and Idiopathic Pulmonary Fibrosis Basel, Switzerland – 28 February 2023Rare Disease Day takes place annually on the last day of February to raise awareness for the more than 7,000 rare diseases and their impact on patients’ lives. Physicians, patients, patient advocates, researchers and medical & biotech companies from around the world shine a light on these little-known diseases and champion the need for education, research funding and access to treatment.Alentis has chosen to spread the word through a team event showing support for patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis and Idiopathic…

Alentis names Markus Meyer COO and promotes Alberto Toso to SVP Head Oncology and Geoffrey Teixeira to SVP Head Fibrosis Basel, Switzerland – 17 February 2023 Alentis Therapeutics (“Alentis”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced the appointment of Markus Meyer to Chief Operations Officer (COO), Geoffrey Teixeira to SVP Head Fibrosis, Alberto Toso to SVP Head Oncology, effective 15 February.In his new role, Markus will be responsible for leading the development of Alentis’ portfolio of monoclonal antibodies that are highly selective in targeting exposed and non-junctional Claudin-1 (CLDN1). Alentis’ pipeline includes…